Publications by authors named "James Luu"
Article Synopsis
- This study aimed to evaluate the long-term efficacy, safety, immunogenicity, and pharmacokinetics of the ranibizumab biosimilar SB11 compared to the original ranibizumab (RBZ) in patients with neovascular age-related macular degeneration (nAMD).
- Conducted as a multicenter, randomized, double-masked, parallel-group phase III equivalence trial with 705 participants, the study involved monthly intravitreal injections of either SB11 or RBZ and followed participants for 52 weeks.
- Results showed comparable visual outcomes, safety profiles, and immune responses between SB11 and RBZ, confirming that SB11 is a suitable alternative to RBZ in treating nAMD.
Article Synopsis
- Neovascular age-related macular degeneration is a major cause of blindness in people over 50, and the ranibizumab biosimilar (SB11) could provide a more accessible treatment option.
- A phase 3 study involving 705 participants was conducted across 75 centers in multiple countries to compare the efficacy, safety, and immunogenicity of SB11 to the reference drug ranibizumab.
- Results showed that the visual acuity and central subfield thickness improvements were similar between the two treatments, indicating that SB11 is a viable alternative to ranibizumab.
This study evaluates the effect of sildenafil on choroidal vascular congestion and its correlation with visual effects. Thirteen healthy subjects were randomized to a sildenafil group (n = 7, 3 M, 4 F), who received 200 mg of sildenafil, and a control (n = 6, 5 F, 1 M) group, who received no drug. Measurements of choroidal thickness with ultrasonography, color vision with Desaturated Panel D-15 Test, and contrast sensitivity with CSV-1000e charts (Vector Vision) were performed at baseline and at 90 and 180 min.
View Article and Find Full Text PDF